Multiple Sclerosis (02:12)
Damaged spinal cord and brain nerve cell covers disrupt communication in the nervous system, causing physical and mental symptoms; it is progressive or relapsing. The Charcot Neurologic Triad establishes diagnostic criteria; George Schumacher attempts to standardized criteria in 1965.
Multiple Sclerosis is the most common central nervous system autoimmune disorder; see maps of geographical distribution rates. Studies suggest migration affects the risk of developing MS; the disease is more common in women.
Central nervous system inflammation is the primary cause of damage. Genetics, environmental factors, and infectious agents are possible elements that influence MS development.
Relapse-Remitting Multiple Sclerosis affects approximately 85% of patients. Spinal cord and brain white matter demyelination and inflammatory infiltrates typically accompany exacerbations. Approximately 15% of patients experience Primary-Progressive MS; two thirds of RRMS patients eventually experience PPMS. White matter plaque is classified as active or inactive.
Diagnosis & Evaluation (09:28)
Physicians employ multiple strategies for diagnosis; doctors must locate damage in two separate areas of the central nervous system that occurred at least a month apart. The McDonald criteria provide specific guidelines; learn red flags for other diagnoses. Early intervention is helpful.
Treatment Options & Management Planning (13:07)
Strategies can modify the disease course, treat relapses, manage symptoms, and improve function; MS is incurable. Treatment aspects include symptomatic treatment and immunomodulatory therapy; patients often benefit from a multidisciplinary approach.
Current Research (12:29)
MS research includes pathogenesis and heterogeneity investigation, new RRMS treatments, progressive subtype therapies, neuroprotection strategies, genetic studies, and effective symptomatic treatment.
A definitive cause of MS remains unknown, but researchers have made progress in the development of new treatments and are making headway in most fields related to the demyelinating disease.
Credits: Multiple Sclerosis: Recent Advances in Diagnostics and Treatment Options (02:04)
Credits: Multiple Sclerosis: Recent Advances in Diagnostics and Treatment Option
For additional digital leasing and purchase options contact a media consultant at 800-257-5126
(press option 3) or email@example.com.